Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at $7.44. Traded volume was 1.38million shares in the last session … Continue reading Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Ryan Holtz06/26

Small Cap Insider Buying: Hercules Offshore (NASDAQ:HERO), Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros Corporation (NASDAQ:OMER), Insys (NASDAQ:INSY), New Mountain Finance (NYSE:NMFC)

Hercules Offshore Inc (NASDAQ:HERO) Director Thomas R. Bates, Jr. purchased 20,000 shares of the stock on the open market in a transaction that occurred on Tuesday, June 24th. The stock was purchased at an average price of $3.93 per share, for a total transaction of $78,600.00. Following the completion of the transaction, the director now directly owns 280,000 shares in the company, valued at approximately … Continue reading Small Cap Insider Buying: Hercules Offshore (NASDAQ:HERO), Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros Corporation (NASDAQ:OMER), Insys (NASDAQ:INSY), New Mountain Finance (NYSE:NMFC)

Kristen Barton06/26

Gilead Sciences GILD NASDAQ:GILD

Hot Biotech Watch List: InterMune Inc (NASDAQ:ITMN), Merrimack Pharmaceuticals (NASDAQ:MACK), China Biologic Products (NASDAQ:CBPO), VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA)

InterMune, Inc. (NASDAQ:ITMN) on 27 May 2014 announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2010. Pirfenidone is being developed for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF). InterMune Inc (NASDAQ:ITMN) stock performance was -0.88% in last session and finished … Continue reading Hot Biotech Watch List: InterMune Inc (NASDAQ:ITMN), Merrimack Pharmaceuticals (NASDAQ:MACK), China Biologic Products (NASDAQ:CBPO), VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA)

Kristen Barton05/28

Gilead Sciences GILD NASDAQ:GILD

Biotech GAiners: BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax Corp. (NASDAQ:DYAX), Novavax, Inc. (NASDAQ:NVAX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares closed up nearly 11% on Tuesday after the company reported positive data from its OPuS-1 mid-stage study involving BCX4161 as a treatment for hereditary angioedema, or HAE. This is a rare immune disorder that can cause swelling of the face, breathing airways, and also causes abdominal cramping. According to the preliminary results from the company’s proof-of-concept study, BCX4161 met both … Continue reading Biotech GAiners: BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax Corp. (NASDAQ:DYAX), Novavax, Inc. (NASDAQ:NVAX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Kevin Long05/28

Recent Insider Buying: AOL, Inc. (NYSE:AOL), Tyco International Ltd. (NYSE:TYC), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Emerson Electric Co. (NYSE:EMR)

AOL Inc (NYSE:AOL) CEO Timothy M. Armstrong purchased 55,600 shares of AOL Inc (NYSE:AOL) stock in a transaction that occurred on Thursday, May 8th. The stock was purchased at an average cost of $36.08 per share, for a total transaction of $2,006,048.00. AOL, Inc. (NYSE:AOL) stock performance was 3.71% in last session and finished the day at $37.74. Traded volume was 3.27million shares in the … Continue reading Recent Insider Buying: AOL, Inc. (NYSE:AOL), Tyco International Ltd. (NYSE:TYC), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Emerson Electric Co. (NYSE:EMR)

Jason Knox05/12